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Abstract: Objective: To review the pharmacology and pharmacokinetics, and to evaluate the clinical efficacy, safety, and 
place in therapy of mipomersen sodium (Kynamro
®
) for the treatment of familial hypercholesterolemia (FH). 
Data Sources: A literature search through Pub Med and clinicaltrials.gov (1984–May 2014; English language) was 
performed using the key words: homozygous familial hypercholesterolemia (HoFH), heterozygous familial 
hypercholesterolemia (HeFH), FH, dyslipidemia, apolipoprotein B-100 (apoB-100), low density lipoprotein cholesterol 
(LDL-C), antisense oligonucleotides (ASOs), and ISIS 301012. Searches were limited to published studies in humans. 
Study Selection and Data Extraction: All articles in English identified from reviews, abstracts, presentations, and clinical 
trials of mipomersen in humans were selected and included. 
Data Synthesis: Mipomersen sodium (Kynamro
®
), an oligonucleotide inhibitor of apoB-100 synthesis, is approved for 
reducing apoB-100, LDL-C, total cholesterol (TC), and non-high density lipoprotein cholesterol (non-HDL-C) in HoFH 
patients as an adjunctive treatment with other lipid lowering drugs and low fat diet. 
Conclusion: Mipomersen is effective in decreasing LDL-C, apoB-100, TC, and non-HDL-C in patients that are refractory 
to other lipid lowering drugs. Mipomersen is administered as 200 mg subcutaneous (s.c.) once weekly injection. The 
drug is contraindicated in patients with moderate to severe hepatic impairment. The most common adverse reactions 
include injection site reaction (ISRs), influenza-like symptoms and increases in serum hepatic transaminase. Kynamro
®
 
is only available through restricted program under Risk Evaluation and Mitigation Strategy (REMS) called Kynamro
®
 
REMS 
Keywords: HoFH, HeFH, FH, ASO, ISIS 301012, LDL-C. 
INTRODUCTION 
Familial hypercholesterolemia (FH) is an autosomal 
lipid metabolism disorder that is characterized by 
lifelong significant elevations in LDL-C and apoB-100 
levels resulting in increased risk of atherosclerosis and 
cardiovascular disease (CVD) [1, 2]. FH can be catego- 
rized into HeFH and HoFH. The prevalence of HeFH is 
approximately 1 in 300 to 500 worldwide and as high 
as 1 in 100 among African, Lebanon, Finland and 
Quebec populations. The prevalence of HoFH is esti- 
mated to be about 1 in one million people of the same 
populations
 
[1-4].
 
HeFH patients under the age of 20 
years usually have LDL-C levels of 190 mg/dL or 
higher, and those older than 30 years may have LDL-C 
levels above 250 mg/dL [3]. HoFH which is a more 
severe form of FH, are seen in early childhood. If this 
disease is left untreated, HoFH patients will die before 
the age of 30 [5-7].  
Several hypotheses exist regarding FH. It can be 
due to mutation in the LDL-receptors (LDLRs) genes, 
apoB-100 genes, pro-protein convertase subtilisin/  
kexin type 9 genes (PCSK9), or a rare mutation in 
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the LDLR adaptor protein 1 (LDLRAP1) genes [3-5],  
[8-12]. About 85% of FH cases are due to mutations in 
LDLRs genes, in which over 1600 mutated genes have 
been identified. A single nucleotide substitution or large 
structural rearrangement of LDLRs gene has been 
identified [3, 9]. Mutations in apoB-100 genes can 
cause defective clearance of atherogenic lipoproteins 
from plasma, due to ApoB-100 plays important roles in 
the packaging and distribution of dietary and endoge- 
nous cholesterol and triglyceride (TG). ApoB-100 also 
plays important role in the lipid metabolism, and in 
providing structural core for other atherogenic lipopro- 
teins such as LDL-C, very low density lipoprotein 
cholesterol (VLDL-C), and lipoprotein (a) [Lp (a)].  
Mutations in PCSK9 genes can lead to either 
hypercholesterolemia (HC) or increased risk of prema- 
ture CVD. This is due to the role of the PCSK9 genes 
in enhancing intracellular degradation of LDLRs and in 
preventing the number of LDLRs at the hepatocyte cell 
surface [10]. When there is an increase in LDLRs 
expression, there is a parallel increased in the PCSK9 
synthesis showing its important role in preventing 
excessive reuptake of cholesterol into cells [11]. The 
LDLRAP1 genes play important role in trafficking LDLR 
into the liver. Mutations in these genes have been 
found in FH autosomal dominant or recessive patients 
[2, 12].  
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Current therapies for the treatment of FH includes 
diet and lifestyle modifications, cholesterol-lowering 
drugs, lipid apheresis or liver transplantation [1]. 
Lifestyle modifications are aiming to lower LDL-C and 
other risk factors of CVD [1]. However, only a minimal 
reduction in LDL-C is usually achieved even when 
patients have very restricted diet such as taking less 
than 200 mg cholesterol per day [1]. Statins are the 
most common, safe and effective drugs used to lower 
LDL-C in FH patients. While HeFH response well to 
statins, HoFH patients response rate to statins is less 
predictable. Reduction of LDL-C from 6% to 50% have 
been seen in HeFH patients [13]. Patients who require 
greater LDL-C reduction usually need to use combina- 
tion of statins with other lipid lowering drugs such as 
ezetimibe, niacin, fibrates, or bile acid sequestrants [2]. 
Options for HoFH patients who are refractory or 
resistant to statins include lipid apheresis or liver 
transplantation. Lipid apheresis procedure removes 
apoB-100 from blood circulation, but this procedure is 
time consuming, costly and gives unpredictable results 
[14]. It is difficult to optimizing the frequency of lipid 
apheresis due to the fluctuation in serum cholesterol 
after the procedure [14]. Several successful liver trans- 
plantation have been performed to HoFH patients, 
however, limited donor organs and the need for ongo- 
ing post-operative immunosuppressant made this pro- 
cedure is less preferable [1, 14]. 
Other approaches to decrease LDL-C in HeFH and 
HoFH patients includes cholesterol ester transfer pro- 
tein (CETP) inhibitors which reduce transfer of 
cholesterol esters from HDL-C to LDL-C, microsomal 
transfer protein (MTP) inhibitors which inhibit the asse- 
mbly of VLDL, PCSK9 inhibitors which regulate LDLR 
degradation, and antisense oligonucleotide (ASO) 
which prevents formation of functional proteins [15-17].  
The Food and Drug Administration (FDA) of USA 
approved mipomersen sodium (Kynamro
®
) as an 
orphan drug for the treatment of HoFH as an adjunctive 
treatment with other lipid lowering drugs and low fat 
diet. The European Union approved this drug for HoFH 
and for severe form of HeFH. Mipomersen is adminis- 
tered as a 200 mg s.c. injection once weekly to reduce 
LDL-C, apoB-100, TC, and non HDL-C levels [18, 19].  
PHARMACOLOGY 
Mipomersen sodium (ISIS 301012 or ISIS 147764, 
Genzyme Corporation, Isis Pharmaceuticals) is a 
synthetic 20-mer 2’-O-(2-methoxy) ethyl- modified 
oligonucleotide, a second generation single stranded 
ASO with specific complementary binding to the coding 
region of human apoB-100 messenger RNA (mRNA) 
[nucleotide 3249-3269] [20]. This inhibitor has 20 
nucleotides with coding sequences as 5’-GCCTCAG- 
TCTGCTTCGCACC-3”, and it is chemically stabilized 
via a phosphorothioates backbone [21]. The center 
nucleotide region of mipomersen is incorporated with 
2’-deoxyribose sugars: 2’-O-methyl (2’OMe) and 2’-O-
methoxyethyl (2’MOE) modified ribose in 3’ and 5’ 
flanking regions of mipomersen. These substitutions 
differentiate the second from the first generation [21]. 
ASOs are designed to specifically bind to apoB-100 
mRNA preventing the translocation of mRNA into 
forming functional apo-B 100 [22-24]. Endogenous 
RNAase enzymes such as RNAse H or Arganaute 2 
recognize the duplex apo B-100 mRNA and 
mipomersen, degrade the mRNA strand; therefore, 
functional apoB-100 protein is not formed [25, 26]. 
Besides degradation by the enzymes, apoB-100 is not 
expressed due to improper splicing of pre-mRNA into 
mature and functional mRNA [21, 23]. Figure 1 showed 
the structure of mipomersen. Figure 2 showed the 
mechanism of action of mipomersen sodium [27].  
In nature, apoB exists in two isoforms: apoB-48 and 
apoB-100. ApoB-48 is a truncated form of apoB-100. It 
is only expressed in the intestine to absorb fat. ApoB-
100 is a large amphipathic protein that is mainly 
produced in the liver. It functions as a carrier of 
cholesterol in the bloodstream. It is present on all 
lipoprotein particles such as LDL-C, VLDL-C, and Lp 
(a) that are responsible for atherosclerosis formations 
[28]. Inhibiting apoB-100 synthesis is significantly 
caused decrease in plasma TC, VLDL-C, LDL-C, and 
Lp (a), while the advantage of inhibiting apoB-48 
formation is unknown [8, 21]. As a second generation 
ASO, mipomersen is better than the first generations 
ASO due to it has greater potency and affinity, has 
enhanced stability to the degradation by enzyme 
nucleases, has longer half-life, and cause less adverse 
reactions [21,24,27, 29-32]. The first gene- 
ration ASO is easily degraded by endonucleases and 
exonucleases and has been demonstrated to be toxic 
to cell growth and proliferation of healthy tissue [33].  
PHARMACOKINETICS AND DRUG-DRUG INTERAC- 
TIONS 
Mipomersen showed similar plasma under curve 
either given as an intravenous (i.v.) infusion or s.c. 
routes in healthy individuals. Plasma concentration of 
mipomersen after 2-hours i.v. was reported from 4.8 to 
21.5 μg/mL when variable i.v. loading doses of 50 to 
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200 mg were administered. Plasma concentration after 
s.c. injection from loading doses of 50 mg to 200 mg 
also showed similar result like i.v. route. Absorption 
was nearly complete following s.c. injection; therefore, 
for future formulation and most clinical trials, s.c. 
injection is used. The median time for mipomersen to 
reach maximum plasma concentration (Cmax) was from 
3.4 to 4 hrs [34]. The elimination half -lives were 23 
(±1) days and 31 (±11) days in 50-mg and 200-mg 
group, respectively [24]. One week after the last dose 
of 50 mg to 400 mg/week doses, the mean plasma 
trough concentrations of mipomersen were reported 
from 8 to 51 ng/mL. Plasma trough concentration 
reached steady state after 2 weeks [34]. ASO is 
metabolized into 7-14 nucleotides of the parent compo- 
und, and then the parent compound and its metabolites 
are excreted in the urine [32]. 
Mipomersen is highly bound to plasma proteins (the 
fraction of mipomersen bound to protein is 93-96% in 
  
Figure 1: Structure of mipomersen from reference number [27]. 
 
 
Figure 2: Mechanism of action of mipomersen. (A): Mipomersen binds sequence specifically to the apoB mRNA to provide a 
substrate for RNase H1, which hydrolyzes the apoB mRNA strand to inhibit apoB synthesis. (B): Inhibition of apoB synthesis by 
mipomersen reduces production of atherogenic apoB-containing lipoproteins by the liver [27]. 
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human plasma over a concentration range of 1-20 
umol/L). The drug has weak dissociation constant [35]. 
Mipomersen distributes into most tissues with volume 
of distribution of 48.3 L/kg. The highest concentrations 
of drug are detected in the liver and kidney. The drug is 
poorly distributed into the skeletal muscle, and it does 
not cross the blood brain barrier [35]. 
Mipomersen does not inhibit or induce any major 
cytochrome p450 enzymes such as CYP1A2, CYP2C9, 
CYP 2C19, CYP2D6 or CYP3A4; therefore, no clinica- 
lly relevant interactions of mipomersen with other drugs 
metabolizing by these enzymes have been reported [8, 
20]. Moreover, concomitant administration of mipomer- 
sen and simvastatin or ezetimibe did not cause signifi- 
cant changes on the pharmacokinetics properties of all 
drugs. There is no difference in half-life of mipomersen 
when it is taken by itself or in combination with simvas- 
tatin or ezetimibe [35]. There is no literature report the 
interaction of mipomersen and herbal products. 
CLINICAL TRIALS  
Data from Phase 1 Clinical Trials 
The first phase 1, double-blind, randomized, 
placebo-controlled, dose-escalation clinical trial was 
conducted to determine the efficacy and tolerability of 
mipomersen in 36 patients with mild dyslipidemia age 
18 to 65 years [24]. The 36 patients were randomized 
into five different groups receiving s.c. placebo, or a 
single s.c. dose of 50, 100, 200 or 400 mg mipomersen 
for 4 weeks (n=7, 8, 8, 9, and 4 patients, respectively). 
After 4 week treatment with placebo or mipomersen, 
there were 4 weeks period of observation in which 
patients didn’t receive any drug. At the end of the 8 
weeks, the patients in each group were given multi-
dose of mipomersen i.v. given at the same assigned 
dose. The i.v. doses were intended to stabilize the 
patients’ hepatic tissues to similar value like the 
baseline. For the next 3 weeks, once weekly s.c. injec- 
tion were given at the same dose assignment. In total, 
a maximum of 12 weeks follow up were conducted to 
observe when the patients’ TC levels had returned to 
greater than 90% of the baseline, whichever occurred 
first. At baseline, patients fasting TC were reported 
from 174 to 290 mg/dL [mean 219 (± 27) mg/dL], LDL-
C ranged from 91 to 173 mg/dL [mean 128 (± 22) 
mg/dL], and apoB-100 ranged from 80 to 140 mg/dL 
[mean 104 (± 23) mg/dL]. Administration of mipom- 
ersen resulted in a dose-dependent reduction of apoB-
100. In the 200 mg dose group, a 50% apoB-100 redu- 
ction from baseline was reported after 72 hrs. which 
was the highest changed reported among the other 
groups (p=0.002). Moreover, in the 200 mg-dose 
group, the TC, LDL-C, TG, and VLDL levels showed 
maximum reductions of 27% (p=0.002), 35% 
(p=0.001), 27%, and 30%, respectively. ApoB-100 and 
LDL-C levels remained significantly below baseline (p < 
0.005) for up to 3 months after the least dose. The 
most common adverse reactions reported was an ISR 
show- 
ing as erythema (72% of incidence) which did not wor- 
sen upon repeated dosing [22, 24]. Table 2 listed other 
adverse drug reactions from different clinical trials. 
In total, there were eight phase 1 clinical trials 
recruited a total of 308 healthy or patients having mild 
to moderate HC as described in Gebhard et al. [36]. 
These trials recruited from 18 to 84 patients with 
different time lines of treatment, with mipomersen 
ranged from 24 hrs. 8 days to 13 weeks. Some patients 
received i.v. or s.c. injections. The aggregate results of 
these clinical trials showed that mipomersen caused 
maximum reduction of apoB-100 for up to 50% and 
LDL-C for up to 35% from the baseline. The levels of 
apoB-100 and LDL-C remained below baseline for up 
to 3 months after the last dose [36].  
Data from Phase 2 Clinical Trials 
Five phases 2 clinical trials were designed to 
evaluate mipomersen effects in patients having mild to 
moderated HC, in HC patients taking statin therapy, or 
in HeFH patients as an add-on therapy [34, 36-38]. A 
phase 2 randomized, double bind, multi-center, 
placebo controlled clinical trial recruited 44 HeFH 
patients age 18 years to 75 years to examine the 
efficacy and safety of mipomersen as an add-on thera- 
py [38]. While on the study, these patients also continu- 
ed taking other lipid lowering drugs such as statin, 
ezetimibe, or bile acid sequestrants. The inclusion 
criteria were HeFH patients with LDL-C greater than 
200 mg/dL (5.2 mmol/L) and at least having one 
additional criteria: the presence of known mutation in 
the LDLR gene, the presence of cutaneous xanthomas, 
history of having adult first-degree relatives with LDL-C 
greater than 190 mg/dL (4.9 mmol/L) or having a child 
younger than 18 years with LDL-C greater than 130 
mg/dL (3.4 mmol/L), or history of first degree relatives 
having early CVD at age less than 55 years for male 
and less than 60 years for female. The exclusion 
criteria include: having prior CVD surgical intervention, 
having history of hepatic, renal, or uncontrolled 
endocrine disorders, having serum creatinine phospho- 
kinase level greater than or equal to three times of 
Mipomersen Sodium (Kynamro
®
) for Familial Hypercholesterolemia Journal of Clinical Medicine Research Updates, 2014, Vol. 1    5 
upper limit normal (ULN), or having hepatic alanine 
aminotransferase (ALT) levels greater than or equal to 
two times of ULN [38]. The patients were randomly 
assigned to placebo (n=8) or s.c. mipomersen 50 mg 
(n=8), 100 mg (n=8), 200 mg (n=11), or 300 mg (n=9) 
group, respectively. The patients received mipomersen 
on days 1, 4, 8, and 11, followed by additional once-
weekly doses on days 15, 22, 29 and 36. In the 300 mg 
dose group, patients received additional 7 weeks of s.c. 
mipomersen on days 43, 50, 57, 64, 71, 78, and 85 
[38]. After 6 weeks of treatment, statistically significant 
reduction of apoB-100 and LDL-C levels were observ- 
ed in 200 mg and 300 mg group. Mean reduction of 
apoB-100 was 23% in 200 mg (p < 0.05) and 33% in 
300 mg (p < 0.01) group, respectively, and reduction in 
LDL-C was 21% in 200 mg (p < 0.05) and 34% in 300 
mg (p< 0.01) group, respectively. Moreover, statistically 
significant reduction of apoB-100 level by 37% and 
LDL-C level by 37% were reported in the group given 
additional of 7 weeks of 300 mg SC mipomersen. 
Three months after the last dose, continual reduction in 
apoB-100 and LDL-C levels to below baseline were 
observed [38]. The most common adverse reaction 
was 97% of ISR. Other adverse drug reactions are 
listed on Table 2. Concomitant administration of mipo- 
mersen with simvastatin or ezetimibe did not caused 
significant effect on the pharmacokinetics properties of 
all the drugs. The result of this phase 2 clinical trial 
showed that mipomersen can be given in combination 
with statins or ezetimibe to further decreasing apoB-
100 levels in HeFH patients. Mipomersen is meta- 
bolized by nucleases, therefore its level is not effected 
by combination with other drugs [35, 39].  
In total, there were five phase 2 clinical trials 
recruited 194 patients with HeFH or HC patients as 
described in Gebhard et al. [36]. The aggregate results 
of these phase 2 trials showed significant reductions in 
apoB-100 and LDL-C levels ranged from 21% to 47% 
in patients taking mipomersen as a single agent or as 
an add-on to statins. Because of the undesirable 
adverse reactions of mipomersen at 300 mg or 400 mg 
in phases 1 and 2 clinical trials in different population 
with variable dyslipidemia conditions, for phase 3 trials 
and hereafter, the dose of mipomersen is determined 
as s.c. 200 mg given once weekly. 
Data from Phase 3 Clinical Trials 
Five randomized, double blind, placebo control 
phase 3 clinical trials were conducted in patients with 
HoFH or HeFH. The latest of phase 3 clinical trial is 
described below, whereas the other four are listed in 
Table 1. [7, 40-42]. The most recent planned interim 
analysis, open label extension trial recruited 141 FH 
patients (103 HeFH and 38 HoFH) who had 
successfully completed a phase 3 clinical trial was 
reported. This report observed the long-term efficacy 
and safety of mipomersen for 104 weeks or up to 4 
years [43]. These patients received s.c. 200 mg 
mipomersen once weekly and maximal tolerated 
dosage of other lipid lowering drugs. Inclusion criteria 
were successfully completed phase 3 trial, did not have 
abnormalities of liver blood test (AST or ALT), having 
tolerable ISR or influenza-like syndrome, not having 
new or worsening condition that interfere with the 
study, and were willing to limit alcohol consumption to 
moderate amounts (males 2 drinks (20 g) per day, 8 
drinks per week; female 1 drink (10 g) per day, 4 drinks 
per week). The mean changed in LDL-C levels from 
baseline on 26, 52, 76, and 104 weeks were -28%, -
27%, -27%, and -28%, respectively. The mean 
changed in apoB-100 levels from baseline on 26, 52, 
76, and 104 weeks were -29%, -28%, -30%, and -31%, 
respectively. Median changes in Lp (a) from baseline 
on 26, 52, 76, and 104 weeks were -21%, -19%, -18%, 
and -17%, respectively, while mean increased in HDL-
C level from baseline on 26, 52, 76, and 104 weeks 
were 6%, 6%, 3%, and 10 %, respectively. Mean 
reduction in TC and non-HDL-C levels were consistent 
with the mean reduction in LDL-C and apoB-100 levels. 
The elimination plasma half-lives were from 14.3 to 105 
days (median of 35 days). All patients experienced at 
least one ISR and had at least one episode of 
influenza-like syndrome. However, the frequency of 
ISRs decreased by 67% after 24 months. There was an 
increase in hepatic transaminase during the first 6-12 
months, but with continual injection, the level didn’t 
change overtime [43].  
ADVERSE REACTIONS, CONTRAINDICATION, AND 
SAFETY 
Common and less common adverse reactions of 
phase 1, 2 and 3 are listed on Table 2. ISR happens in 
at least 98% of the cases, but it is generally self-
limiting, and mild to moderate in severity. Every patient 
experiences at least one ISR during the treatment. 
Influenza-like symptoms that started within 2 days after 
the mipomersen injection affects about 65% of the 
patients. It is the most frequent cause of drug 
discontinuation.  
Mipomersen sodium is contraindicated in patients 
with moderate to severe hepatic impairment (Child 
Pugh category of B or C) or active liver disease 
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presenting as unexplained persistent elevation of liver 
transaminases (ALT or AST) to equal or greater than 3 
times ULN [43].  
Mipomersen can cause elevations in liver 
transaminases and hepatic fat (steatohepatitis) which 
can progress to cirrhosis with or without an increased 
in the transaminase levels. If symptoms of hepatoto- 
xicity or liver injury are noticed such as nausea, 
vomiting, abdominal pain, fever, jaundice, lethargy, 
increased in bilirubin to equal or greater than 2 times 
ULN, or increased in liver transaminases to equal or 
greater than 3 times ULN, the mipomersen treatment 
should be discontinued. 
Table 1: Summary of 4 other Phase 3 Clinical Trials of Mipomersen Sodium [7, 40-42] 
Study Design Patients Outcomes Results 
Raal et al. 
(2010) [7] 
R, PC, DB, MC 
200 mg/week for 
26 weeks 
Evaluate safety 
and efficacy of 
mipomersen 
n= 51 HoFH  
  MIP (n=34), PL (n=17) 
Inclusion: LDL-C > 131 mg/dL and xanthoma 
before 10 yo, or have HeFH parents, on low fat 
diet, take statins, ezetimibe, bile acid 
sequestrants, or combination of the drugs 
 
Exclusion: have lipid apheresis the previous 8 
weeks, significant CVD events within 12 weeks, 
CHF, uncontrolled hypothyroidism, unstable 
angina, hyperlipidemia, or renal or hepatic 
disease, have liver transaminase  3 x ULN 
Primary: 
percentage in LDL-
C reduction 
 
 
 
 
Secondary: 
percentage change 
in apoB, TC, HDL-
C, Lp(a), TG 
MIP: LDL-C* -25 %  
 apoB* -27 % 
 TC -21 % 
 non HDL-C -25 % 
 ratio of LDL/HDL-C -34% 
 HDL-C +15 % 
 
PL: ratio of LDL/HDL-C 6% 
 
Stein et al. 
(2012) [40] 
R, PC, DB, MC 
200 mg/week for 
26 weeks 
Evaluate safety 
and efficacy of 
mipomersen as 
an add-on 
therapy 
n= 124 HeFH with CVD 
 MIP (n=83), PL (n= 41) 
Inclusion: HC with LDL-C  100 mg/dL, TG  
200 mg/dL, maximum tolerated statin with or 
without other lipid lowering drugs 
 
 
Exclusion: have lipid apheresis the previous 8 
weeks, DM, unstable angina, CHF, 
hyperlipidemia, having AST or ALT  1.5 x 
ULN, or having renal or hepatic disease. 
Primary: 
percentage LDL-C 
reduction 
 
 
 
 
Secondary: 
percentage change 
in apoB, TC, HDL-
C, Lp(a), TG 
MIP: LDL-C* -28 %  
 apoB* -26 % 
 TC -19 % 
 Non HDL-C* -25 % 
 VLDL-C -14 % 
 TG -14 %  
 HDL-C +3 % 
 Ratio LDL/HDL-C* -29 % 
PL: LDL-C + 5 % 
apoB +7 % 
TC +4 % 
Non HDL-C +4 % 
HDL-C +6 % 
Ratio LDL/HDL-C -3 % 
Thomas  
et al. 
(2013) [41] 
R, PC, DB, MC 
200 mg/week for 
26 weeks 
Stratified to  
40% patients 
have T2DM 
Evaluate safety 
and efficacy of 
mipomersen 
n= 157 HC with CVD  
 MIP (n=105), PL (n=52) 
Inclusion: HC with LDL-C > 100 mg/dL and high 
risk for atherosclerosis on low-fat diet and 
maximally tolerated statin therapy.  
 
Exclusion: significant CVD events with 24 
weeks of screening, HF, HTN, T1DM, 
hyperlipidemia, or having renal or hepatic 
disease. 
Primary: 
percentage LDL-C 
reduction 
 
 
 
Secondary: 
percentage change 
in apoB, TC, HDL-
C, Lp(a), TG 
MIP: LDL-C*-37%  
 apoB*-38% 
 HDL-C+2% 
 TG-26%  
 Lp(a)-24% 
 TC-26% 
PL: LDL-C-5% 
apoB-4% 
HDL-C+2% 
TG+11% 
TC-3% 
McGowan  
et al. 
(2012) [42] 
R, PC, DB, MC, 
 200 mg/week for 
26 weeks 
Evaluate safety 
and efficacy of 
mipomersen 
n= 58 severe HeFH  
MIP (n=39), PL (n=19) 
Inclusion: HeFH, have LDL-C  300 mg/dL 
without CHD, or  196 mg/dL with CHD on 
maximally tolerated lipid lowering therapy and 
are not on apheresis. 
 
Exclusion: active apheresis, significant CVD 
events with 24 weeks of screening, CHF, HTN, 
hyperlipidemia, or having renal or hepatic 
disease. 
Primary: LDL-C 
reduction from 
baseline to 2 
weeks after the 
last dose 
 
 
Secondary: 
percentage change 
in apoB, TC, HDL-
C, Lp (a), TG 
MIP: LDL-C* -36 %  
 apoB* -36 %  
 non HDL-C -34 %  
 TC-28 %  
 
 
 
PL:  LDL-C +12 %  
apoB +11 % 
non HDL-C +14%  
TC+11 %  
Abbreviation: p values v. placebo; *p  0.001 all populations; R, randomized; OL, open-labeled; DB, double-blind; PC, placebo-controlled; MC, multi center; HC, 
hypercholesterolemia; CHD, coronary heart disease; CHF, congestive heart failure; HTN, hypertension; MIP, mipomersen; PL, placebo; DM, diabetes mellitus; LDL-
C, low density lipoprotein cholesterol; Lp (a), lipoprotein (a); ApoB, apolipoprotein; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; 
ULN, upper limit of normal; FH, familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia 
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Because this risk of hepatotoxicity, mipomersen is 
only available through a restricted program called 
Kynamro
®
 risk evaluating and mitigation strategy 
(REMS), in which only certified healthcare providers 
and pharmacies may prescribe and distribute this drug 
[44]. Patients should have a full liver, total bilirubin and 
alkaline phosphatase tests before the initiation of the 
treatment and thereafter tested depending on the levels 
of the hepatic transaminases. The goals of REMS 
program are to educate healthcare providers and 
patients about the risk of hepatoxicity, to ensure  
 
Table 2: Adverse Drug Reactions from some Phase 1-3 
Clinical Trials [24, 37, 40] 
Clinical Phase Adverse Drug Reactions 
Phase 1 
Study by 
Kastelein  
et al. [24] 
MIP: ISR (erythema, pruritus, irritation, 
discoloration, pain, swelling, bruising, 
induration, warmth, rash and 
hematoma) 72% 
Influenza- like symptoms (pyrexia, 
chills, myalgia, arthralgia, malaise) 70% 
Increase in TG 0.8 %  
PL: ISR 9 % 
Influenza-like symptoms 18 %  
Decrease in TG 0.1 % 
Phase 2 
Study by Akdim  
et al. [37] 
MIP: ISR 90 % 
Headache 31 % 
Influenza-like symptoms 25 % 
Fatigue 19 % 
Nasopharyngitis 17 % 
Back pain 17 % 
Urinary tract infections 10% 
Pyrexia 10% 
Increase in ALT to  3 x ULN 17 % 
PL:  ISR 13 % 
Headache 40 % 
Influenza- like symptoms 7 % 
Nasopharyngitis 7 % 
Back pain 7 % 
Increase in ALT to  3 x ULN 7 % 
Phase 3 
Study by Stein  
et al. [40] 
MIP:  ISR 93% 
Influenza- like symptoms 49 % 
Nausea 17 % 
Headache 18 %  
Diarrhea 11 % 
Nasopharyngitis 11 % 
Cough 11 % 
Increase in ALT to  2x ULN 41 % 
        3x ULN 36%  
PL : ISR 42 %,  
Influenza- like symptoms 32 % 
Nausea 14 % 
Headache 17 %  
Diarrhea 12 % 
Nasopharyngitis 7 % 
Cough 5 % 
Increase in ALT to  2x ULN 34 % 
        3x ULN 7 % 
Abbreviation: MIP, mipomersen; PL, placebo; ISR, injection site reaction; 
ULN, upper limit normal; ALT, alanine aminotransferase; TG, triglyceride. 
patients to have their liver being monitored, and to 
restrict use of mipomersen to patients with HoFH or 
severe HeFH only [44]. 
DOSING, ADMINISTRATION AND STORAGE 
In the clinical trials, the maximum tolerated dose of 
mipomersen was defined as 200 mg s.c. injection given 
once weekly. Mipomersen sodium is available as a 
single dose of prefilled s.c. syringe or a single vial 
containing 1 mL of 200 mg mipomersen of colorless to 
slightly yellow solution. The s.c. injection should be 
given in abdomen, thigh or upper arm. The drug should 
be stored in refrigerator at 2°C to 8°C (36°F and 46°F) 
[19, 45]. It should reach room temperature at least 30 
mins before the administration. If refrigerator is not 
available, it can be stored at or below 30°C (86°F), 
away from heat sources for up to 14 days [19, 45].  
USE IN SPECIFIC POPULATIONS 
Although the pregnancy category of mipomersen is 
B, there were no adequate and well-controlled studies 
have been done in pregnant women. Studies in 
pregnant animal showed that there was no harm to the 
fetus. Although it is not known if mipomersen is 
excreted into human milk, however, caution should be 
exercised when mipomersen is administered to nursing 
mother.  
There was no specific guideline from the 
manufacture regarding use of mipomersen in pediatric 
population although a clinical trial recruited patients 
younger than 18 years had been conducted in which 7 
out of the 51 were pediatric. There were no differences 
in adverse reactions in the patients younger than 18 
years or in older patients group. The mipomersen 
prescribing information states, “Safety and effective- 
ness of mipomersen has not been established in 
pediatrics [19].”
 
More clinical trials are needed to recruit 
pediatric patients to determine the safety and 
effectiveness of mipomersen in this population. 
Patients older than 65 years old may experience 
higher incidence of hypertension and peripheral 
edema, but the percentage of the incidence is not 
reported [19].
 
Hepatosteatosis incidence was greater in 
patients older than 65 years (13.6%) vs. 10.4% in 
patient younger than 65 years old [19].
 
ECONOMIC INFORMATION 
Many patients with CVD, severe dyslipidemia, or 
elevated Lp (a) levels need aggressive treatment to 
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lower theirs LDL-C, apoB-100, or Lp (a) levels. Patients 
with HoFH usually respond less effectively to statins 
than HeFH patients. Additionally, HoFH or HeFH 
patients usually require lipid apheresis as the treatment 
option to extra corporeally removing unwanted LDL-C 
from the blood [46, 47]. Using lipid apheresis 
procedure, a reduction of about 53% in LDL-C level are 
seen with weekly or biweekly procedure (from average 
19 mmol/L in untreated to 12 mmol/L in treated 
patients) [46].  
Currently in the USA, there are estimated of about 
315 HoFH patients and 650,000 HeFH patients [48]. 
The estimated cost for a lipid apheresis is $4,000 per 
procedure. Patients who have weekly procedure will 
pay $208,000 per year, not counting traveling from their 
homes to one of the 35 lipid apheresis sites available in 
the USA [49].  
The cost of mipomersen per month is $16,269 per 4 
injection or $ 176,228 per year [50]. Another drug that 
is currently approved by FDA for the treatment of HoFH 
is lomitapide (Juxtapid
®
). Lomitapide has pregnancy 
category of X, is an oral drug available at 5, 10 or 20 
mg for the cost of $27,156 per 28 capsules. This drug 
can be taken as 5mg to 60 mg daily for an annual cost 
ranged from $235,000 to $ 295,000 [51]. Comparing 
the cost of mipomersen to lipid apheresis or lomitapide, 
a patient can save from $59,000 to $119,000 annually. 
SUMMARY  
Mipomersen sodium given as an s.c. injection once 
weekly at dose of 200 mg/vial is effective in lowering 
LDL-C, apoB-100, TG, TC and Lp (a) levels in patients 
with severe HC, HeFH or HoFH as shown in several 
phase1, 2 and 3 clinical trials. Mipomersen provides 
significant additional reduction in apoB-100 atherogenic 
lipoproteins which is difficult to treat in HoFH or HeFH 
patients, although these patients usually already 
treated with maximal dose of lipid lowering drugs such 
as statins or ezetimibe. Mipomersen does not cause 
drug-drug interactions with other drugs or lipid lowering 
drugs which provides advantage to the patients who 
need to take combination of mipomersen and other 
lipid lowering drugs. Common adverse reactions are 
ISR, influenza-like symptoms, and increase in ALT or 
AST levels. Although the clinical significant of the 
increased in AST, ALT and/or liver fat content that are 
occurring in some patients remains uncertain, 
mipomersen was found to not causing increased risk of 
steatohepatitis or hepatocellular inflammation [45].
 
The 
recently open label clinical trial confirmed the safety 
profile of mipomersen for up to 2 years showing similar 
profile when it is taken for shorter duration such as 26 
weeks. There was also a returned in the liver fat con- 
tent toward baseline after 1 year treatment. This sho- 
wed liver has ability to adapt to the drug. Establishing 
baseline liver function prior to initiation of mipomersen 
treatment follows by regular monitoring liver test is 
highly recommended. Mipomersen is available only 
from certified healthcare providers and pharmacies. 
The US FDA approved mipomersen with black box 
warning of causing increased risk of hepatic 
impairment, as an orphan drug for HoFH patients as an 
adjunctive treatment to currently available lipid lowering 
drugs. 
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